STOCK TITAN
  1. Home
  2. News
  3. AVXL

Anavex Life Sciences Corporation - AVXL STOCK NEWS

Welcome to our dedicated news page for Anavex Life Sciences Corporation (Ticker: AVXL), a resource for investors and traders seeking the latest updates and insights on Anavex Life Sciences Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Anavex Life Sciences Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Anavex Life Sciences Corporation's position in the market.

News
Anavex Life Sciences Provides an Update on Rett Syndrome Program
Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) announced topline results from the Phase 2/3 EXCELLENCE clinical study in pediatric Rett Syndrome. The study evaluated the clinical efficacy, safety, and tolerability of 30 mg ANAVEX®2-73 in 92 pediatric patients. The study showed improvement in the Rett Syndrome Behaviour Questionnaire (RSBQ) but did not meet the Clinical Global Impression – Improvement scale (CGI-I). Anavex believes a high placebo response may have masked the therapeutic effect of the drug. A preliminary review of the safety results indicates no new safety signals in the study. Over 91% of patients completing the trial continued into a 48-week open-label extension study (OLE), which is ongoing. The company has established Compassionate Use Programs in Canada, Australia, and the UK for pediatric patients. ANAVEX®2-73 has previously received Fast Track designation, Rare Pediatric Disease designation, and Orphan Drug designation from the FDA for the treatment of Rett syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.07%
Tags
none
-
News
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome
Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) announced the first entire clinical gene pathway data from the ANAVEX®2-73-RS-002 AVATAR Rett syndrome trial. The study confirmed that Rett syndrome is a neurodevelopmental disorder with a key metabolic component, addressable with therapeutic intervention. The ANAVEX®2-73 treatment showed significant activation of key developmental and metabolic gene pathways, potentially compensating for dysregulated genes. The study included 33 patients with Rett syndrome and analyzed gene expression changes, single nucleotide polymorphisms/variants, and transcriptomics analysis. The results highlighted significant differences between the active treatment group and placebo, suggesting potential correction of metabolic alterations in patients with Rett syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.06%
Tags
none
-
News
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has deemed oral blarcamesine for Alzheimer’s disease eligible for submission of a Union Marketing Authorisation in the EU under the centralised procedure. Anavex aims to submit the Marketing Authorisation Application in 2024. Blarcamesine addresses a broader Alzheimer’s disease population compared to monoclonal antibodies and has shown significant improvement in dementia symptoms and reduction of pathological aggregation of amyloid in early Alzheimer’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.2%
Tags
none
News
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) reported financial results for its fiscal year ended September 30, 2023, with key pipeline updates for Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and more. The company also highlighted recent business and financial highlights, including the grant of a new patent, initiation of a Marketing Authorisation application, and appointment of a new Senior Vice President. The company's cash and cash equivalents stood at $151.0 million at September 30, 2023, with a net loss of $10.1 million for the fourth quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.04%
Tags
earnings
-
News
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) will issue financial results for its fiscal year ended September 30, 2023, on November 27, 2023. The company is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative and neurodevelopmental disorders. A conference call will be held to review financial results and provide an update on the execution of the Company’s growth strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
earnings
-
News
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or Anxiety
Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) announced the grant of U.S. Patent No. 11,813,242 entitled 'A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY, AND AGITATION.' This patent expands the company's existing patent coverage of ANAVEX®2-73 (blarcamesine), ANAVEX®1-41, and ANAVEX®19-144 for treating insomnia, anxiety, and agitation. The patent is expected to remain in force until July 2037, providing extensive coverage for the company's lead compounds. Anavex aims to deliver holistic care for patients with Alzheimer’s dementia or Parkinson’s diseases, who often concurrently suffer from insomnia and/or anxiety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
News
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)
Rhea-AI Summary
Anavex Life Sciences Corp. (Nasdaq: AVXL) met with the European Medicines Agency to discuss blarcamesine (ANAVEX®2-73) Alzheimer’s disease clinical program results. Anavex initiated the process for submitting a Marketing Authorisation application to the EMA for oral blarcamesine. The goal is to allow direct access to the European Union market for the treatment of Alzheimer’s disease. An estimated 7 million people in Europe have Alzheimer’s disease, with costs of care estimated at $439 billion in 2019. Anavex aims to provide convenient oral treatment options for Alzheimer’s patients, addressing the urgent need for simple patient-centered administrations and shared decision-making.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.64%
Tags
none
-
News
Anavex Life Sciences Appoints Senior VP of Regulatory Affairs
Rhea-AI Summary
Anavex Life Sciences Corp. has appointed David Goldberger as Senior Vice President Regulatory Affairs. Goldberger brings over 40 years of experience in pharmacy practice and the pharmaceutical industry, with expertise in regulatory strategies and global interactions for CNS development projects. He will succeed Emmanuel O Fadiran, who is retiring. Goldberger has previously led regulatory efforts for CNS products at Otsuka Pharmaceuticals and Johnson and Johnson. Anavex is a clinical-stage biopharmaceutical company focused on developing therapeutics for neurodegenerative and neurodevelopmental disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
management
-
News
Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease
Rhea-AI Summary
Anavex Life Sciences Corp. has reported a new study that shows the potential disease-modifying properties of ANAVEX®3-71 (AF710B) in Alzheimer's disease. The study found that ANAVEX®3-71 treatment prevented cognitive decline and reduced amyloid and neuroinflammation in a transgenic rat model of Alzheimer's disease. The drug candidate could be a promising option for a once daily oral preventive strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.97%
Tags
none
News
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
Rhea-AI Summary
Anavex Life Sciences Corp. announces significant reduction in amyloid beta biomarkers of Alzheimer's pathology in Phase 2b/3 study with blarcamesine (ANAVEX®2-73)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
clinical trial
Stock AVXL logo
Anavex Life Sciences Corporation

Nasdaq:AVXL

AVXL Rankings

#3475 Ranked by Market Cap
#4851 Ranked by Stock Gains
N/A Ranked by Dividends

AVXL Stock Data

338.30M
79.52M
3.14%
32.12%
26.94%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About AVXL

anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.